Nimotuzumab
Nimotuzumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target epidermal growth factor receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
102 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nasopharyngeal neoplasms | D009303 | — | 8 | 4 | 1 | — | 13 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | 2 | 1 | — | 3 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Esophageal squamous cell carcinoma | D000077277 | 1 | 8 | 3 | — | — | 9 | ||
| Squamous cell carcinoma of head and neck | D000077195 | — | 4 | 1 | — | 3 | 8 | ||
| Uterine cervical neoplasms | D002583 | 1 | 6 | 2 | — | — | 8 | ||
| Esophageal neoplasms | D004938 | C15 | — | 5 | 3 | — | — | 7 | |
| Neoplasms | D009369 | C80 | 2 | 3 | 1 | — | — | 6 | |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 3 | 1 | — | — | 4 |
| Head and neck neoplasms | D006258 | — | 2 | 2 | — | — | 4 | ||
| Diffuse intrinsic pontine glioma | D000080443 | — | 1 | 1 | — | 1 | 3 | ||
| Immunotherapy | D007167 | — | — | 2 | — | — | 2 | ||
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | 2 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 4 | 8 | — | — | 2 | 11 | ||
| Colorectal neoplasms | D015179 | 2 | 4 | — | — | — | 4 | ||
| Lung neoplasms | D008175 | C34.90 | 2 | 4 | — | — | — | 4 | |
| Squamous cell carcinoma | D002294 | — | 3 | — | — | — | 3 | ||
| Chemoradiotherapy | D059248 | — | 2 | — | — | — | 2 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Oropharyngeal neoplasms | D009959 | — | 1 | — | — | — | 1 | ||
| Hypopharyngeal neoplasms | D007012 | C13 | — | 1 | — | — | — | 1 | |
| Penile neoplasms | D010412 | C60 | — | 1 | — | — | — | 1 | |
| Brain stem neoplasms | D020295 | EFO_1001767 | — | 1 | — | — | — | 1 |
Show 7 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nasopharyngeal carcinoma | D000077274 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NIMOTUZUMAB |
| INN | nimotuzumab |
| Description | Nimotuzumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >3GKW:H|Heavy chain of the antibody Nimotuzumab
QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAY
MELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVP
>3GKW:L|Light chain of the antibody Nimotuzumab
DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTI
SSLQPEDIATYYCFQYSHVPWTFGQGTKLQITREVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ
SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 3GKW |
| CAS-ID | 828933-51-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108359 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 6NS400BXKH (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
EGFR
EGFR
Organism
Homo sapiens
Gene name
EGFR
Gene synonyms
ERBB, ERBB1, HER1
NCBI Gene ID
Protein name
epidermal growth factor receptor
Protein synonyms
avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, EGFR vIII, epidermal growth factor receptor tyrosine kinase domain, erb-b2 receptor tyrosine kinase 1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1
Uniprot ID
Mouse ortholog
Egfr (13649)
epidermal growth factor receptor (Q01279)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,769 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
38 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more